About the PI
Weiping Zou serves as Director of the Michigan Center of Excellence for Cancer Immunology and Immunotherapy, Co-Director of the Cancer Hematopoiesis and Immunology Program and directs the Immunologic Monitoring Core at the University of Michigan School of Medicine and Rogel Cancer Center. He also directs the Surgical Oncology Fellow Training (T32) program, through which clinical fellows are trained to become physician scientists with a focus on cancer immunology and immunotherapy. At the national level, he was the AACR Cancer Immunology (CIMM) Chairperson 2019-2020 and has served as the Cancer Immunology Abstract Programming Chair for AAI in the last 4 years. He has delivered more than 300 invited lectures at different institutions and conferences and published more than 170 articles and book chapters, including 28 articles in Nature, Science, and Cell journal series. His laboratory is one of the most cited research teams in the field of immunology. Their work has been highlighted by many scientific news agencies. “Specific recruitment of regulatory T cells inovarian carcinoma fosters immune privilege and predicts reduced survival”, an original work on human Tregs, has been cited more than 4,000 times since its publication. Weiping Zou has developed an international reputation in human tumor immunology and immunotherapy.